Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02285582 · ClinicalTrials.gov registry record
International Rare Histiocytic Disorders Registry (IRHDR)
A clinical trial of Erdheim-Chester Disease (ECD) and Rosai-Dorfman Disease (RDD), sponsored by The Hospital for Sick Children.
- Recruiting
- Registry status
- 400
- Enrollment target
- 15
- Study locations
NCT02285582: Recruiting study of Erdheim-Chester Disease (ECD) and Rosai-Dorfman Disease (RDD), sponsored by The Hospital for Sick Children.
NCT02285582 is a study of Erdheim-Chester Disease (ECD) and Rosai-Dorfman Disease (RDD) that is actively recruiting participants, run by The Hospital for Sick Children. The registered enrollment target is 400 participants. The trial reports 15 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02285582, a study of Erdheim-Chester Disease (ECD) and Rosai-Dorfman Disease (RDD), is actively recruiting participants, sponsored by The Hospital for Sick Children.
- RECRUITING
- Registry status
- 400 participants
- Enrollment target
- 15
- Study locations
Study Summary
The rare histiocytic disorders (RHDs) are characterized by the infiltration of one or more organs by non-LCH histiocytes. They can range from localized disease that resolves spontaneously, to progressive disseminated forms that can be sometimes life-threatening. Since they are extremely rare, there is limited understanding of their causes and best treatment options. Physicians, patients and parents of children with RHDs frequently consult members of the Histiocyte Society regarding the best management of these disorders. Very often, no specific recommendation can be made due to the lack of prospective outcome data, or even large retrospective case series. The creation of an international rare histiocytic disorders registry (IRHDR) could facilitate a uniform diagnosis of the RHDs, as well as the collection and analysis of the clinical, epidemiological, treatment and survival data of patients with RHD. The registry may also lead to future therapeutic recommendations, provide a framework for future clinical trials and create excellent research opportunities.
Primary Outcome
Collecting data on disease presentation, treatments used and treatment outcomes over time for patients diagnosed with RHD to better understand the diseases and optimize the treatments. Data will be analysed on average yearly, the registry will be ongoing for 10 years.
Conditions Studied
Interventions
- OTHER Registry study
Study Locations (15)
Other
- Hospital Nacional de Pediatria Garrahan - Buenos Aires
- University Hospital Brno - Brno
- Rostock University Medical Hospital - Rostock
- Azienda Ospedaliero-Universitaria Meyer - Florence
- Children's Memorial Health Institute - Warsaw
- Hospital Universitario Cruces - Barakaldo
California
- Children's Hospital of Los Angeles - Los Angeles
- Valley Children's Hospital - Madera
Alabama
- The University of Alabama at Birmingham - Birmingham
Massachusetts
- Dana-Farber Cancer Institute - Boston
New York
- Memorial Sloan Kettering Cancer Center - New York
Pennsylvania
- University of Pittsburgh Medical Center - Pittsburgh
Ontario
- The Hospital for Sick Children - Toronto
Quebec
- Centre hospitalier universitaire Sainte-Justine - Montreal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2014-10 |
| Est. Completion | 2028-09 |
What NCT02285582 shows while recruiting
NCT02285582 is an observational study that tracks outcomes without assigning an intervention. The registered 400 participants enrollment target is mid-sized for trials with a published cap.
The record links to 10 conditions, with Erdheim-Chester Disease (ECD) appearing as the primary indexed condition, and to 1 intervention - of which Registry study is the first listed.
NCT02285582 lists 15 locations in 9 states (Other, California, Alabama).
Frequently Asked Questions
What is clinical trial NCT02285582 about?
NCT02285582 is a clinical study titled "International Rare Histiocytic Disorders Registry (IRHDR)". The rare histiocytic disorders (RHDs) are characterized by the infiltration of one or more organs by non-LCH histiocytes. They can range from localized disease that resolves spontaneously, to progressive disseminated forms that can be sometimes life-threatening. Since they are extremely rare, there ...
What is the current status of trial NCT02285582?
This trial is currently recruiting. The enrollment target is 400 participants. The study started on 2014-10. Estimated completion is 2028-09.
What conditions does trial NCT02285582 study?
This clinical trial studies the following conditions: Erdheim-Chester Disease (ECD), Rosai-Dorfman Disease (RDD), Rare Histiocytic Disorders (RHDs), Xanthogranuloma Family (XG), Indeterminate Dendritic Cell Histiocytosis.
What interventions are being tested in trial NCT02285582?
The interventions under investigation include: Registry study (OTHER).
Who is sponsoring clinical trial NCT02285582?
This trial is sponsored by The Hospital for Sick Children, which has 23 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02285582 being conducted?
This trial has 15 study locations across Alabama, California, Massachusetts, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Erdheim-Chester Disease (ECD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01665326 · 400 participants
Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease
- NCT02108054 · 400 participants · NA
Behavioral and Functional Task Development, Implementation, and Testing
- NCT02216500 · 400 participants · NA
Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy
- NCT02250352 · 400 participants
Core Biopsies for Establishing a Breast Tumor Tissue Repository
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia